Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Open accessThe DOI matches its Crossref record; 131 of the 136 references it cites were found in a registry or an index.
Abstract
Irinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expanding. The pharmacogenetics of the drug is the crucial component of response to irinotecan. Furthermore, new formulations of the drug are introduced in order to better deliver the drug and avoid potentially life-threatening side effects. Here, we give a comprehensive overview on irinotecan’s molecular mode of action, metabolism, pharmacogenetics, and toxicity. Moreover, this article features clinically used combinations of the drug with other anticancer agents and introduces novel formulations of drugs (e.g., liposomal formulations, dendrimers, and nanoparticles). It also outlines crucial mechanisms of tumor cells’ resistance to the active metabolite, ethyl-10-hydroxy-camptothecin (SN-38). We are sure that the article will constitute an important source of information for both new researchers in the field of irinotecan chemotherapy and professionals or clinicians who are interested in the topic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Mechanisms of action for human topoisomerases. (A) Topoisomerase IA binds to DNA at a particular binding site, and then claves one strand, forming a transient 5′-phosphotyrosyl bond. The other DNA strand is transferred through the resultant break, allowing DNA to relax. Religation ends the process. (B) Toposiomerase IB works in a controlled rotation mechanism and in contrast to type IA enzymes forms a 3′-phosphotyrosyl bond with a DNA molecule. Both type I (A&B) topoisomerases do not require ATP hydrolysis as a source of energy. (C) Topoisomerase II binds to both ends of the DNA molecule, forms a double-strand break, and passes a segment of dsDNA through. This reaction is ATP-dependent [19].](https://figures.cochat.ai/paper-figures/7f178116e98944b58d61966403e83683/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-1.jpg)


![Figure 4 Mechanisms of cell death induced by irinotecan. The ternary irinotecan–topoisomerase I–nicked DNA complex with topoisomerase I (Topo I) inhibitor (SN-38) disables religation of the nicked strand and prevents topoisomerase release. Collision of the formed complex with advancing replication forks results in the formation of double-strand breaks (DSBs). This is followed by DNA damage response (DDR) signaling and TP53-induced gene expression of pro-apoptotic genes such as apoptosis regulator (BAX), phorbol-12-myristate-13-acetate-induced protein 1 (NOXA), or p53 up-regulated modulator of apoptosis (PUMA). Furthermore, down-regulation of the Bcl-2-like protein 1 isoform protein (BCL-xL) protein allows BAX and Bcl-2 homologous antagonist (BAK) embedding into the mitochondrial membrane and the formation of pores that allow the release of cytochrome C (cytC) from mitochondria and the subsequent formation of apoptosome with apoptotic protease-activating factor 1 (APAF-1) protein and procaspase-9. The activation of procaspase to caspase 9 (Casp-9) results in proteolytic cleavage and the conversion of procaspase 3 into active caspase 3 (Casp-3), which executes apoptosis [37,38,44,49,51].](https://figures.cochat.ai/paper-figures/e0271a41931a4560ab503b6a9b0123a1/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-4.jpg)
![Figure 5 Overview of irinotecan metabolism. CPT-11 is a prodrug that is converted to active metabolite ethyl-10-hydroxy-camptothecin (SN-38) by liver carboxylesterase converting enzymes (CES1/2) and is then transported to the liver by 1B1 polypeptide (OATP1B1) and inactivated by microsomal uridine 5′-diphospho-glucuronosyltransferase enzymes (UGTs): UGT1A1 and UGT1A9. Irinotecan is transported to bile by a group of the ATP-binding cassette transporters (ABC transporters): ABCB1, ABCC1, ABCC2, and ABCG2. Irinotecan is efficiently metabolized by cytochrome P450 enzymes: CYP3A4 and CYP3A5. This results in the generation of less active metabolites APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin) and NPC (7-ethyl-10-[4-amino-1-piperidino] carbonyloxycamptothecin). NPC (but not APC) can be further converted to SN-38 by CES1, and CES2 gut microbiota may also participate in irinotecan metabolism by the production of β-glucuronidase, which catalyzes the breakdown of SN-38G to SN-38. The inhibition of topoisomerase I (TOP1) results in DNA damage, replication fork arrest, and apoptotic cell death [53,54,55,56,57,58,59,60,61,62].](https://figures.cochat.ai/paper-figures/5036a4be7c55479baa6b8b63ea3ebd23/irinotecanstill-an-important-player-in-cancer-chemotherapy-a-comprehensive-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Irinotecan (IRI) is a chemotherapeutic agent that inhibits topoisomerase I activity, which in turn inhibits both DNA replication and transcription49.”
From A statistical framework for high-content phenotypic profiling using cellular feature distributions (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredIn the citing paper
“Irinotecan exerts a cytotoxic effect by inhibiting DNA replication and transcription by targeting topoisomerase 1 (TOP-1) [87].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apoptosis: A Review of Programmed Cell Death
Elmore, S. (2007) · Toxicologic Pathology · doi:10.1080/01926230701320337 · Cited by 13,853
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
DNA Topoisomerases: Structure, Function, and Mechanism
Champoux, J. J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.369 · Cited by 2,743
Cellular roles of DNA topoisomerases: a molecular perspective
Wang, J. C. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm831 · Cited by 2,353
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
Self-citationVauthey, J.-N., Pawlik, T. M., Ribero, D., Wu, T.-T., Zorzi, D., Hoff, P. M., Xiong, H. Q., Eng, C., Lauwers, G. Y., Mino-Kenudson, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.3074 · Cited by 1,300
Cited by
Items 101–200 of 266
Mneimneh, A. T., Darwiche, N., & Mehanna, M. M. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124473 · Cited by 12
Li, L., Li, C., Chang, P. M., Lai, T., Yong, C.-Y., Feng, S., Hsiao, M., Chang, W., & Huang, C. F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.775541 · Cited by 13
dos Santos, I. W. F., da Silva, K. S., Bueno, L. R., Schneider, V. S., Schiebel, C. S., de Oliveira, N. M. T., da Silva, L. C. M., Fernandes, E. S., Góis, M. B., Cordeiro, L. M. C., et al. (2023) · Nutrition and Cancer · doi:10.1080/01635581.2023.2191382 · Cited by 10
“trexate, irinotecan, and 5-fluorouracil (2,5,6), act by”
Shivanna, A. T., Dash, B. S., Lin, Y.-J., Lin, W., & Chen, J. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124856 · Cited by 11
The potential of kaempferol in digestive system tumors: recent advances and mechanistic insights
Hao, X., Ding, M., Chi, C., Xu, X., Zhang, X., & Hu, M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01510-2 · Cited by 13
“Irinotecan, a semi-synthetic analog of the plant alkaloid camptothecin, is currently widely used for the treat-ment of colorectal cancer, esophageal cancer, gastric cancer, non-small cell lung cancer, and small cell lung cancer as a topoisomerase I inhibitor [102].”
Yuan, F., Jiang, Y., Yang, L., Lu, D., Li, N., Zhang, Q., Yang, H., Qin, H., Zhang, J., Gou, X., et al. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2453730 · Cited by 11
“…trapping, permanent DNA strand breaks and cell death [59]. irinotecan and its active metabolite SN-38 inhibit topoisomerase i, creating SSBs that become lethal during DNA replication. these agents show particular effectiveness against Sclc and are often used in combination with platinum drugs [60].”
Yadav, R., Chary, P. S., Bhalerao, H. A., Srivastava, V., Pardhi, E. R., Pawar, A., Sonti, R., & Mehra, N. K. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00567 · Cited by 11
Suksiriworapong, J., Achayawat, C., Juangrattanakamjorn, P., Taresco, V., Crucitti, V. C., Sakchaisri, K., & Bunsupa, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082100 · Cited by 11
“The anticancer mechanism of SN-38 involves the inhibition of topoisomerase I [69].”
BackgroundMaryiam, A., Batool, S., Ali, Z., Zahid, F., Alamri, A. H., Alqahtani, T., Fatease, A. M. A., Lahiq, A. A., Khan, M. W., & Din, F. U. (2024) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2024.2448334 · Cited by 9
“Over years, it has been utilized to treat malignancies alone or in combination (Kciuk et al. 2020).”
Understanding microRNA-Mediated Chemoresistance in Colorectal Cancer Treatment
Valenzuela, G., Contreras, H. R., Marcelain, K., Burotto, M., & González‐Montero, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031168 · Cited by 11
Cao, J., Hang, K., Zhang, H., Wu, Z., Guo, Z., Men, J., Tian, J., & Li, K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177964 · Cited by 13
Mei, C., Sun, Z., Tan, L., Gong, J., Li, X., & Liu, Z. (2022) · Cell Proliferation · doi:10.1111/cpr.13208 · Cited by 10
Multifunctional delivery strategies and nanoplatforms of SN-38 in cancer therapeutics
Lozano-García, M., Dikici, E., Bilbao, D., Mohan, P., Deo, S. K., & Daunert, S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113937 · Cited by 12
Clement, E. J., Law, H. C.-H., Qiao, F., Noe, D., Trevino, J. G., & Woods, N. T. (2022) · Cancers · doi:10.3390/cancers14081968 · Cited by 10
Wang, X., Yu, C., Sun, Y., Liu, Y., Tang, S., Sun, Y., & Zhou, Y. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108253 · Cited by 9
Banu, H., Al-Shammari, E., Shahanawaz, S., Azam, F., Patel, M. B., Alarifi, N. A., Ahmad, M. F., Adnan, M., & Ashraf, S. A. (2025) · Pharmaceuticals · doi:10.3390/ph18040453 · Cited by 9
Yang, Z., Cao, Z., Wang, W., Chen, Y., Huang, W., Jiao, S., Chen, S., Chen, L., Liu, Y., Mao, J., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106625 · Cited by 8
ANTI-CANCER MEDICINS (CLASSIFICATION AND MECHANISMS OF ACTION)
Hussein, A., Hussein, K., Babkair, H. A., & Badawy, M. (2024) · Egyptian Dental Journal /Egyptian Dental Journal · doi:10.21608/edj.2023.234480.2708 · Cited by 13
“Creating a ternary combination between DNA and the topoisomerase II complex by etoposide stop binding of DNA strands, makes degeneration to DNA constitutions (36) .”
BackgroundChen, Z., Yang, R., Zhu, C.-W., Li, Y., Yan, R., & Wan, J. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c02339 · Cited by 7
Jurič, A., Karačonji, I. B., Gašić, U. M., Milojković‐Opsenica, D., Prđun, S., Bubalo, D., Lušić, D., Vahčić, N., & Kopjar, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031903 · Cited by 8
He, S., Wang, Y., Qi, J., Chen, H., & Zhou, W. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105848 · Cited by 7
Natural medicines target tumor vascular microenvironment to inhibit tumor
Lu, Y., Guo, Z., Li, H., Wen, J., Zhang, X., Guan, X., Cui, X., & Cheng, M. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101623 · Cited by 9
“131 In liver cancer, camptothecin has been observed to modulate the epithelial e mesenchymal transition by influencing the expression of key markers.”
Xu, Y., Qin, C., Zhang, M., Wu, Q., Li, Z., Mo, H., Chen, C., Zhou, A., Li, J., & Ni, W. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.06.013 · Cited by 12
Iimori, Y., Morita, T., Masuda, T., Kitajima, S., Kono, N., Kageyama, S., Galipon, J., Sasaki, A. T., & Kanai, A. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf789 · Cited by 9
Li, J., Chu, C., Chao, W., Yeh, C.-S., Lee, Y., Chen, D.-C., Yang, S., & Chao, Y. (2023) · Aging · doi:10.18632/aging.204695 · Cited by 7
Sontakke, A. D., Gupta, P., Banerjee, S. K., & Purkait, M. K. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.132621 · Cited by 8
Zhang, H., Zhang, X., Ma, X., & Wang, X. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00684-4 · Cited by 8
“Irinotecan (IRN), commonly used in cancer treatment, often causes severe adverse effects [ 98, 99].”
Zhao, D., Wu, D., Zhang, G., Li, Y., Shi, W., Zhong, B., & Yu, H. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07652-2 · Cited by 7
“Recent studies found that irinotecan (CPT-11), a classic chemotherapeutic agent, has certain advantages in the treatment of refractory CRC [4, 5].”
BackgroundInfluentialZheng, K., Yuan, S., Dong, M., Zhang, H., Jiang, X., Yan, C., Ye, R., Zhou, H., Chen, L., Jiang, R., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i20.3103 · Cited by 7
Targeting of neuroblastoma cells through Kynurenine‐ AHR pathway inhibition
dos Santos, I. L., Mitchell, M., Nogueira, P. A. S., Lafita‐Navarro, M. C., Perez‐Castro, L., Eriom, J., Kilgore, J. A., Williams, N. S., Guo, L. M., Xu, L., et al. (2024) · FEBS Journal · doi:10.1111/febs.17109 · Cited by 7
Lai, Z., Zhang, Y., Huang, W., Wang, D., Liu, C., Ren, M., Huang, X., Chen, J., Xie, J., Chen, B., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157071 · Cited by 8
Exogenous/endogenous stimuli-responsive antitumor prodrugs advance precision chemotherapy
Wang, L., Li, J., Zeng, X., Lu, Q., Wang, Y., Anwar, Z., Li, X., Fan, H., & Sun, H. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118485 · Cited by 9
Xing, P., Wang, S., Bi, M., Liu, Y., Zeng, J., Wang, X., Ke, X., Li, W., Guo, J., Wang, P., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102791 · Cited by 6
Almajidi, Y. Q., Althomali, R. H., Maashi, M. S., Ahmad, I., Saleh, E. A. M., Kareem, A. K., Romero‐Parra, R. M., Alawsi, T., & Salim, K. S. (2023) · Diamond and Related Materials · doi:10.1016/j.diamond.2023.110015 · Cited by 6
Zou, Y., Wang, Y., Zhou, W., & Pei, J. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1208 · Cited by 7
Farrokhnazar, E., Moghbelinejad, S., Najafipour, R., & Teimoori‐Toolabi, L. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e41933 · Cited by 5
Comprehensive metabolomics study identifies SN-38 organ specific toxicity in mice
Zhu, X., Huang, Y., Liu, J., Kong, B., Cui, C., & Han, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-01753-1 · Cited by 5
Therapeutic Effect of Brucea Javanica Oil Emulsion in Mice with Irinotecan-Induced Delayed Diarrhea
Lai, Z., Zhang, Y., Hu, X., Chen, L., Huang, W., Wang, D., Chen, B., Ren, M., Yang, B., Su, Z., et al. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s517973 · Cited by 5
Li, S., Xie, M., Du, Y., & Tan, Z. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02235-7 · Cited by 7
“Collision of Iri-notecan-topoisomerase I-DNA complex with a moving replication fork can lead to the formation of lethal double-strand break (DSB) and replication arrest [16].”
Tseng, J., Yang, J., Lee, C., Lo, C., Liu, Y., Zhang, M. M., Huang, L., Liu, K., Wang, C., Huang, C. F., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81683 · Cited by 5
“Nevertheless, irinotecan causes adverse effects at a higher dose, thereby limiting its therapeutic usage [53].”
BackgroundDeng, C., Liu, Q., Yang, M., Cui, H., Ge, Y., Li, Q., Zhu, S., Yang, G., Zhang, Z., Gao, Y., et al. (2024) · Chinese Medicine · doi:10.1186/s13020-024-01025-6 · Cited by 5
“Irinotecan and its metabolites were released into the intestine via bile, SN-38G reconverts into SN-38 by β-glucosidase in the intestine, causing intestinal mucosal damage and delayed diarrhea, which is the main adverse reaction of irinotecan [3, 4].”
BackgroundHassani, S., Malekinejad, H., Ansari, M. H. K., Abbasi, A., & Kheradmand, F. (2025) · Research in Pharmaceutical Sciences · doi:10.4103/rps.rps_204_24 · Cited by 4
“IRI in combination with 5-FU is usually used in the clinical treatment of CRC (13).”
The lncrnas: innovative multifunctional players of drug resistance in colorectal cancer
Maghsoudi, H., Rasoulzadeh, M., Abbastabar, M., Fazilat, A., Sheikhnia, F., Azizzadeh, B., Valilo, M., & Majidinia, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03951-3 · Cited by 5
“Irinotecan is another drug that inhibits DNA transcription and replication by targeting topoisomerase 1 (TOP-1) [147].”
Nabiyi, S., Heiat, M., & Rezaei, E. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.12.006 · Cited by 6
SN-38-indoximod conjugate: carrier free nano-prodrug for cancer therapy
Kumar, S., Koseki, Y., Tanita, K., Shibata, A., Mizutani, A., & Kasai, H. (2025) · Therapeutic Delivery · doi:10.1080/20415990.2025.2458449 · Cited by 4
Yadav, N., Xiao, A., Zhong, Q., Kumar, P., Konduru, G. V., Hart, W. L., Lazzara, M. J., & Purow, B. W. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05089-8 · Cited by 7
“…downregulation of many genes in the TGF-β family, including its classic target gene, SERPINE1 [7, 36–38] , in both the irinotecan and irinotecan + simvastatin treatment groups; we hypothesize this is likely due to the transcriptional inhibition activities of topoisomerase I inhibitors [58].”
Zhang, L., Hao, M., Yao, L., Xue, L., Yu, J., Xing, D., & Chen, P. (2025) · Food Hydrocolloids for Health · doi:10.1016/j.fhfh.2025.100224 · Cited by 5
Wang, Y., Li, X., Zhu, H., Chen, X., & Wang, H. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125908 · Cited by 4
Harmych, S. J., Hasaka, T. P., Sievers, C. K., Kang, S. W., Ramirez, M. A., Jones, V. T., Zhao, Z., Kovtun, O., Wahoski, C. C., Liu, Q., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08699-0 · Cited by 4
“For this, we elected to focus on the interaction of azithromycin with irinotecan, which is a key component of several chemotherapeutic regimens for the treatment of advanced CRC 29 .”
Wei, P., Fan, X., Shi, H., Jiang, Y., Fan, L., Xing, Y., Peng, Y., He, Y., Zou, W., & Jiang, M. (2025) · Digestive Diseases · doi:10.1159/000548922 · Cited by 7
“Escherichia - Shigella and Enterococcus intensify oxidative stress and epithelial damage, per-petuating inflammatory cascades [63], while β-glucu-ronidase-producing E. coli reactivates the toxic metabolite SN-38 in irinotecan-treated patients, precipitating severe mucosal injury and diarrhea [64].”
Ahmed, M. F., Noman, M. A., Ahmed, M. F., Latif, A., Pappu, M. A. A., Islam, M. S., Hossain, M. S., Hossen, M. B., Faysal, M. F., Hasan, M. M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0335410 · Cited by 5
“It targets MDM2 to activate TP53-mediated apoptosis and thereby effectively halts pAML progression [106].”
Qu, J., He, X., Luo, Y., Yu, P., Chen, Y., Liu, J., Wang, X., Wang, C., Liang, T., Bai, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1072943 · Cited by 4
Mensah, G. A. K., Schaefer, K. G., Bartlett, M. G., Roberts, A. G., & King, G. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216058 · Cited by 4
“TPT and IRT are more soluble, have improved bioavailability, and are less toxic compared to the parent compound [22,23].”
BackgroundLin, Y., Huang, Z., Zhang, B., Yang, H., & Yang, S. (2024) · The Journal of Membrane Biology · doi:10.1007/s00232-024-00308-1 · Cited by 4
“Irinotecan has been employed in the treatment of many malignant tumors over the years (Kciuk et al. 2020), including several decades of application in CRC (Saltz 1998).”
Marsh, D. T., & Smid, S. D. (2024) · Toxicology in Vitro · doi:10.1016/j.tiv.2024.105888 · Cited by 6
Notter, S., Choezom, D., Griebel, T., Ramos‐Gomes, F., Möbius, W., Oliveira, T. D., Conradi, L., Alves, F., & Feldmann, C. (2024) · Small Science · doi:10.1002/smsc.202400196 · Cited by 4
Tamtürk, E., Azarkan, S. Y., Ercan, F. S., & Tunçbilek, A. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206340868241018075528 · Cited by 4
Kenmogne, V. L., Takundwa, M. M., Nweke, E. E., Monchusi, B. A., Dube, P., Maher, H., du Toit, J., Philip-Cherian, V., Fru, P. N., & Raj, D. B. T. G. (2025) · Scientific Reports · doi:10.1038/s41598-025-93634-w · Cited by 4
Molecular relation between biological stress and carcinogenesis
Rakoczy, K., Szlasa, W., Sauer, N. J., Saczko, J., & Kulbacka, J. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-07543-6 · Cited by 5
Kumudhavalli, M. V., & Ramasamy, V. (2025) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3113 · Cited by 3
Phytomolecules from Herbs: Possible Effective Way for the Treatment of Liver Cancer
Mohan, S., Maurya, A., & Singh, R. M. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266321814250228070642 · Cited by 3
Wedmann, B., Kort, S., Pointner, L., Winter, G., Lindner, L. H., & Hossann, M. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125862 · Cited by 3
Ritu, R., Chandra, P., & Das, A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2274968 · Cited by 3
“These side effects can include nausea, vomiting, diarrhea, and decreased blood cell counts (Kciuk et al., 2020; Richardson & Dobish, 2007).”
Faisal, M. S., Hussain, I., Ikram, M. A., Shah, S. B., Rehman, A., & Iqbal, W. (2024) · Journal of Chemotherapy · doi:10.1080/1120009x.2024.2349444 · Cited by 7
“Furthermore, polymorphisms within UGT genes have a substantial impact on irinotecan pharmacokinetics and pharmacodynamics [32,33].”
Ali, S., Nedelcu, D.-M., Serescu, R., & Bumbăcea, R. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13247824 · Cited by 3
Menon, S. V., Juneja, B., Joshi, U. A., Faujdar, M., Chinnathambi, A., Alahmadi, T. A., Arulselvan, P., & Thangavelu, I. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106629 · Cited by 3
Vukadinović, A., Ognjanović, M. R., Mijović, M., Warren, B., Erić, S., & Prijovich, Z. M. (2025) · Pharmaceuticals · doi:10.3390/ph18020177 · Cited by 3
Huang, J., Peng, J., Zhai, E., Wei, R., Qian, C., Li, J., Cai, S., & Ma, J.-P. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01259-z · Cited by 3
“Irinotecan, a topoisomerase I inhibitor, exerts its efficacy by inducing DNA damage and inhibiting DNA repair mechanisms [14].”
Liu, Z., Koseki, Y., Yang, M., Tanita, K., & Kasai, H. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00994d · Cited by 3
Fujita, H., Kataoka, Y., & Kuwahara, M. (2020) · Applied Sciences · doi:10.3390/app10238755 · Cited by 3
Ebrahimpour, M., Mohammadian, M., Pourheydar, B., Moradi, Z., & Behrouzkia, Z. (2022) · Journal of lasers in medical sciences · doi:10.34172/jlms.2022.09 · Cited by 3
Marsh, D. T., & Smid, S. D. (2022) · Food & Function · doi:10.1039/d2fo02458f · Cited by 4
Successful Treatment of Irinotecan-Induced Muscle Twitching: A Case Report
Shun, Y.-T., Lai, H.-Y., Chuang, Y., & Lin, H.-F. (2023) · Clinical Medicine Insights Case Reports · doi:10.1177/11795476221150354 · Cited by 3
Sim, R. R. Y., Yang, C. H., & Yang, Y. Y. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.3c01101 · Cited by 3
Gulnaz, A., Lee, K., Kang, M.-J., Chang, J., & Chae, Y. (2024) · Toxicology Letters · doi:10.1016/j.toxlet.2024.02.011 · Cited by 3
Wang, W., Xiong, H., Li, L., 胡霞林, Hu, X., Li, J., Sun, X., Yu, Y., Yu, Y., Yu, Y., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107436 · Cited by 3
Bera, P., Singh, M. R., Singh, D., & Keshavkant, S. (2025) · BioNanoScience · doi:10.1007/s12668-025-02092-1 · Cited by 2
Regmi, A., Elayyan, M., Nisar, S., & Sui, B. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01434d · Cited by 2
Metastatic microenvironment of extrahepatic cholangiocarcinoma
Gao, R., Wei, B., Li, K., Zou, H., Cao, J., Dong, Q., & Zhu, C. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003852 · Cited by 2
Song, B., Zhang, Y., Wang, L., & Hu, J. (2025) · Medicine · doi:10.1097/md.0000000000046044 · Cited by 2
“[8] Therefore, a comprehensive analysis of ADEs associated with these representative plant alkaloid-based chemotherapeutic agents is essential for optimizing treatment regimens and ensuring patient safety.”
Clinical applications and advancements in camptothecin-based cancer therapies
Dave, R., Patel, R. B., & Patel, M. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-40511-2.00026-7 · Cited by 2
Pan, Y., Chen, L., Hu, Y., Chang, J., Xu, X., Xu, S., Li, Y. H., Du, J., Wang, J., & Xu, W. (2026) · Cancer Medicine · doi:10.1002/cam4.71550 · Cited by 2
“regimen (FOLFIRI), significantly prolonging patient survival [3–6].”
Xu, K., Cui, Z., Ding, Y., Guo, T., Han, J., Yao, Y., Cai, Y., Wei, B., Bao, X., Chen, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00742 · Cited by 3
Boland, P. M., Fountzilas, C. K., Fakih, M., Opyrchal, M., Diamond, J. R., Corr, B. R., Ma, W. W., Redman, M., Chan, W., Wang, H., et al. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04453-z · Cited by 2
“It is a potent anticancer drug with antitumor activity demonstrated in a wide range of tumors including colorectal, gastroesophageal, pancreatic and ovarian cancer [1].”
BackgroundKurella, S., & Addepally, U. (2023) · Current Bioactive Compounds · doi:10.2174/1573407219666230524162346 · Cited by 2
Blume, J., Claus, L., Isermann, T., Dickmanns, A., Conradi, L., Schulz‐Heddergott, R., & Dobbelstein, M. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2217003 · Cited by 2
“Secondly, irinotecan acts most strongly on cells in S phase, since it traps topoisomerase near DNA replication forks, resulting in DNA breaks and apoptosis [24,28].”
BackgroundPotential of Nanomedicines as an Alternative for the Treatment of Colorectal Cancer - A Review
Costa, K. M. N., Barros, L. A., Soares, I. L. D. S., & Oshiro, J. A. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206269415231128100926 · Cited by 2
Harnessing the therapeutic potential of phytochemicals in neuroblastoma
Ahmadi, S. S., Bagherzadeh, O., Sargazi, M., Kalantar, F., Najafi, M. A. E., Vahedi, M. M., Afshari, A. R., & Sahebkar, A. (2024) · BioFactors · doi:10.1002/biof.2115 · Cited by 3
Akagi, T., Hamano, H., Miyamoto, H., Takeda, T., Zamami, Y., & Ohyama, K. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03767-6 · Cited by 2
“Irinotecan, an extremely important anticancer chemotherapy drug, is used to treat several types of cancer [1].”
Liu, J., Minchom, A. R., Greystoke, A., Evans, T. R. J., Sarker, D., Joshua, A. M., Morton, C., Yau, W., Aktaş, B. Y., Cosman, R., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00236 · Cited by 9
Levit, M. L., Sivtsov, E. V., Gostev, A. I., Sinitsyna, E., Dobrodumov, A. V., Bagaeva, I. O., Zakharova, N. V., & Korzhikova‐Vlakh, E. (2025) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2025.106497 · Cited by 2
Effect of irinotecan administration on amiloride‐sensitive sodium taste responses in mice
Obayashi, N., Sakayori, N., Kawaguchi, H., & Sugita, M. (2023) · European Journal Of Oral Sciences · doi:10.1111/eos.12922 · Cited by 2
Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer
Cavalcanti, I. D. L. (2022) · Springer eBooks · doi:10.1007/978-3-031-10839-6_5 · Cited by 2
Yang, Y., Alahmadi, T. A., Alharbi, S. A., & Wainwright, M. (2023) · Materials Express · doi:10.1166/mex.2023.2409 · Cited by 1
Kwon, H., An, J., Kim, J. S., & Kang, I. (2023) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2023.101517 · Cited by 1
“SN-38 is a topoisomerase I inhibitor that binds to DNA Topoisomerase I to form a complex, inhibiting the original role of Topoisomerase I, DNA twist prevention, resulting in double-stranded DNA breakage and cell cycle (M, S phase) arrest and cause cell death [8,11].”
BackgroundUgrappa, S., Jagadeesan, D., Lalitha, P., Ravichandran, M., Solyappan, M., Khor, G. H., Wu, Y. S., Balakrishnan, V., Thangeswaran, D., & Fuloria, S. (2024) · Asian Journal of Chemistry · doi:10.14233/ajchem.2024.31038 · Cited by 1
Singh, V. V., Punia, A., Gupta, S., Thakur, A., Kumar, R., & Chauhan, N. S. (2024) · Reference series in phytochemistry · doi:10.1007/978-3-031-43199-9_58 · Cited by 1
Shen, X., Zhai, H., Tian, W., Lai, L., Ma, T., Chen, X., Wang, C., & Hou, H. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117969 · Cited by 1
Common Drug-Drug and Drug-Food Interactions in Antineoplastic Agents: A short update review
Sanajou, S., & Baydar, T. (2025) · Hacettepe University Journal of the Faculty of Pharmacy · doi:10.52794/hujpharm.1602716 · Cited by 2
Minchev, V. T., Tsankov, H., Robev, B., Takov, M., Federchev, S., Kamenova, K., Todorov, L. T., Atanasova, L., Hristova-Avakumova, N. G., Nikolov, R. P., et al. (2025) · Life · doi:10.3390/life15071071 · Cited by 1
“The latter is a much more potent topoisomerase-I inhibitor, determining efficacy and toxicity [9,10].”
Metadata
- Authors
- Kciuk, M., Marciniak, B., & Kontek, R.
- Affiliations
- University of Łódź (PL)
- Corresponding author
- Kciuk, Mateusz
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-07-12
- Volume
- 21
- Issue
- 14
- Pages
- 4919
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7404108
- OpenAlex
- W3041813955
- Cited by
- 266
- References
- 136
- Citations by year
- 2026: 29 · 2025: 76 · 2024: 66 · 2023: 50 · 2022: 29 · 2021: 13 · 2020: 3
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, camptothecin, SN-38, pharmacogenetics, drug metabolism, drug toxicity, combination chemotherapy, liposomal formulation, dendrimers, nanoparticles, drug resistance, anticancer agents
- MeSH terms
- Irinotecan, Antineoplastic Combined Chemotherapy Protocols, DNA, Neoplasm, Dosage Forms, Drug Compounding, Drug Synergism, Female, Humans, Male, Models, Molecular, Neoplasm Proteins, Neoplasms, Nucleic Acid Conformation, Prodrugs, Protein Conformation, Molecular Structure, Drug Resistance, Neoplasm, Polymorphism, Single Nucleotide, Topoisomerase I Inhibitors, Activation, Metabolic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.